Cell-free DNA mutations as biomarkers in breast cancer patients receiving tamoxifen

The aim was to identify mutations in serum cell-free DNA (cfDNA) associated with disease progression on tamoxifen treatment in metastatic breast cancer (MBC). Sera available at start of therapy, during therapy and at disease progression were selected from 10 estrogen receptor (ER)-positive breast ca...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Oncotarget
Autori principali: Jansen, Maurice P.H.M., Martens, John W.M., Helmijr, Jean C.A., Beaufort, Corine M., van Marion, Ronald, Krol, Niels M.G., Monkhorst, Kim, Trapman-Jansen, Anita M.A.C., Meijer-van Gelder, Marion E., Weerts, Marjolein J.A., Ramirez-Ardila, Diana E., Jan Dubbink, Hendrikus, Foekens, John A., Sleijfer, Stefan, Berns, Els M.J.J.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Impact Journals LLC 2016
Soggetti:
Research Paper
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5190033/
https://ncbi.nlm.nih.gov/pubmed/27270325
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.9727
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi